Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Kevin J. Harrington, Robert I. Haddad, Makoto Tahara et al.|JAMA Oncology|2023

Cited by 73